Survival differences between radiofrequency ablation and surgical resection for early hepatocellular carcinoma: a population-based comparative effectiveness study
In brief
Liver cancer resection linked to 3.9 more survival months than ablation
In a registry study of 2,763 people with localized liver cancer tumors up to 30 mm, surgery was associated with 3.9 more months of restricted mean survival than radiofrequency ablation at 48 months; adjusted overall survival was 17.2 percentage points higher. The gap was smallest for tumors 20 mm or smaller, but this observational comparison cannot prove surgery caused the difference or establish that the treatments are equivalent.
- Journal
- European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology (Q1)
- Published
- 5 November 2026
- Study design
- Unclassified
- Evidence level
- Level 5, Expert Opinion (CEBM 5)
- Authors
- Kehan Lin, Xiangting Ding, Xiaoju Li, Guangliang Huang, Baoxian Liu
- PMID
- 43008614
- DOI
- 10.1016/j.ejso.2026.112361
Why clinicians should know about it
- Picked for Surgical Oncology (paper of the day, 14 November 2026): Population comparison informs resection versus ablation for localized HCC
Abstract
INTRODUCTION: Radiofrequency ablation (RFA) is less invasive than resection for early hepatocellular carcinoma (HCC); randomized trials in small tumors have not demonstrated a significant overall survival difference between the two treatments, whereas observational comparisons have suggested longer survival after resection. MATERIALS AND METHODS: We analyzed data from 17 registries of the Surveillance, Epidemiology, and End Results (SEER) Program (2004-2023) for patients with T1N0M0 HCC ≤30 mm treated with RFA or resection. The primary effect measure was the restricted mean survival time difference (ΔRMST; RFA minus resection) at 24, 36, and 48 months. RESULTS: Among 2763 patients (1287 resection; 1476 RFA), overlap-weighted ΔRMST was -0.58 (95% CI, -0.96 to -0.20), -1.88 (95% CI, -2.61 to -1.16), and -3.86 months (95% CI, -4.99 to -2.73) at 24, 36, and 48 months, respectively; corresponding adjusted overall survival differences were -8.2, -13.5, and -17.2 percentage points. In exploratory subgroup analyses, adjusted differences were smallest for tumors ≤20 mm and largest for tumors 31-50 mm. CONCLUSION: Resection was associated with longer restricted survival than RFA in localized T1N0M0 HCC ≤30 mm; larger negative adjusted estimates were observed at successively longer analysis horizons. The smallest adjusted differences were observed for tumors ≤20 mm, although uncertainty increased at longer follow-up; these estimates may inform treatment discussions but do not establish equivalence. In exploratory analyses of tumors >30 mm, adjusted survival differences were larger and consistently favored resection.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.